ABSI:NSD-Absci Corporation Common Stock (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.80

Change

+0.19 (+2.87)%

Market Cap

USD 0.61B

Volume

0.97M

Avg Analyst Target

USD 10.00 (+47.06%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Absci Corporation Common Stock (ABSI) Stock Analysis:
Based on the Absci Corporation Common Stock stock forecasts from 6 analysts, the average analyst target price for Absci Corporation Common Stock is USD 10.00 over the next 12 months. Absci Corporation Common Stock’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Absci Corporation Common Stock is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Absci Corporation Common Stock’s stock price was USD 6.80. Absci Corporation Common Stock’s stock price has changed by -0.44% over the past week, -2.68% over the past month and +0.00% over the last year.

About

Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the ...Read More

Company Website : https://www.absci.com

Address : 18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683

Employees : 207

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 31.53

Short Ratio : 10.54

52 Week Low : 6.12

Shorted Shares : 3,490,502

200 Day Moving Average : 14.28

Shorted Shares Previous Month : 2,904,689

50 Day Moving Average : 10.17

Shares Held By Insiders : 17.08%

Short Percentage : 5.14%

Shares Held by Institutions : 38.66%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

 USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

 USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

 USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

 USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

 USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

 USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

 USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

 USD17.76B N/A N/A

ETFs Containing ABSI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.07% 42% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.07% 42% F 20% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.61B 71% C- 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.43 60% D- 49% F
Price / Cash Flow Ratio -56.04 94% A 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 21.81% 90% A- 90% A-
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio -4.63% 91% A- 92% A-
Technical Ratios  
Short Ratio 10.54 8% F 5% F
Short Percent 5.14% 42% F 32% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.